Contin M, Riva R, Albani F, Perucca E, Baruzzi A
Ther Drug Monit. 1985;7(1):46-50. doi: 10.1097/00007691-198503000-00007.
The performance of the enzyme multiplied immunoassay technique (EMIT) in the measurement of total and free plasma carbamazepine (CBZ) levels was assessed in 140 clinical specimens and compared with a reference high pressure liquid chromatography (HPLC) technique. Free drug was measured in plasma filtrates obtained by the Free Level system. Both total and free CBZ levels as determined by EMIT correlated strongly with corresponding HPLC values (r = 0.88 and 0.92, respectively). Plasma CBZ concentrations, however, were higher by EMIT than by HPLC. The degree of CBZ overestimation by EMIT was relatively small (about 14%) in whole plasma but quite considerable (35% on average) in the filtrates. As a result, estimated values of free CBZ fraction were also higher for EMIT than for HPLC. Separate experiments in vitro suggested that the discrepancies between the two methods were due to cross-reaction of the EMIT reagent with the 10,11-epoxide metabolite of CBZ. The greater degree of overestimation for the free drug can be explained by the higher proportion of less protein-bound metabolite in the filtrates. These results need to be taken into account in the interpretation of free CBZ level data from laboratories using different techniques.
在140份临床样本中评估了酶放大免疫分析技术(EMIT)在测定血浆总卡马西平(CBZ)和游离卡马西平水平方面的性能,并与参考高压液相色谱(HPLC)技术进行了比较。通过游离水平系统获得的血浆滤液中测定游离药物。EMIT测定的总CBZ和游离CBZ水平均与相应的HPLC值密切相关(分别为r = 0.88和0.92)。然而,EMIT测定的血浆CBZ浓度高于HPLC测定的浓度。EMIT对CBZ的高估程度在全血中相对较小(约14%),但在滤液中相当可观(平均35%)。因此,EMIT测定的游离CBZ分数估计值也高于HPLC测定的。体外单独实验表明,两种方法之间的差异是由于EMIT试剂与CBZ的10,11-环氧化物代谢物发生交叉反应。游离药物高估程度更大的原因可以解释为滤液中与蛋白质结合较少的代谢物比例较高。在解释使用不同技术的实验室提供的游离CBZ水平数据时,需要考虑这些结果。